ÄúÏÖÔÚµÄλÖ㺠Öйú¿Æ¼¼´´ÐÂÍø > ÎÄÕÂÖÐÐÄ > ´´ÐÂÈËÎï°Ù¿Æ > ÉúÃü¿Æѧ > ÎÄÕÂÕýÎÄ
ר¼ÒÐÅÏ¢ ¿ÆѧÑо¿ ÂÛÎÄרÖø ÈÙÓþ½±Àø ýÌ屨µÀ

ר¼ÒÐÅÏ¢£º


ÖÜÐñÓÄУ¬1972Äê³öÉú£¬²©Ê¿¡£ÏÖÈÎÖйú¿ÆѧԺ΢ÉúÎïËùÑо¿Ô±¡¢²©Ê¿Éúµ¼Ê¦£¬µ÷½ÚÐÔTϸ°ûÑо¿×é¿ÎÌâ×鳤£¬ÖпÆÔº¡°°ÙÈ˼ƻ®¡±ÈëÑ¡Õß¡£

½ÌÓý¼°¹¤×÷¾­Àú£º

1989Äê9ÔÂÖÁ1993Äê7ÔÂɽ¶«´óѧÉúÃü¿ÆѧԺ΢ÉúÎïϵ΢ÉúÎïѧרҵ£¬»ñÀíѧѧʿѧλ¡£

1993Äê9ÔÂÖÁ1996Äê7ÔÂɽ¶«Å©Òµ´óѧֲ±£ÏµÖ²ÎﲡÀíרҵ£¬»ñÀíѧ˶ʿѧλ¡£

1996Äê12ÔÂÖÁ1997Äê3ÔÂÈÕ±¾´óÚæ´óѧ£¬´óѧԺҽѧϵÑо¿¿Æ²¡Àíרҵ£¬Ö×Áö·¢ÉúѧÑо¿ÊÒ£¬½øÐÞÉú¡£

1997Äê4ÔÂÖÁ2001Äê3ÔÂÈÕ±¾´óÚæ´óѧ£¬´óѧԺҽѧϵÑо¿¿Æ²¡Àíרҵ£¬Ö×Áö·¢ÉúѧÑо¿ÊÒ£¬»ñҽѧ²©Ê¿Ñ§Î»¡£

2001Äê4ÔÂÖÁ2002Äê3ÔÂÈÕ±¾´óÚæ´óѧ£¬´óѧԺҽѧϵÑо¿¿Æ²¡Àíרҵ£¬Ö×Áö·¢ÉúѧÑо¿ÊÒ£¬½»Á÷ѧÕß¡£

2002Äê4ÔÂÖÁ2003Äê9ÔÂÈÕ±¾´óÚæ´óѧ£¬´óѧԺҽѧϵÑо¿¿Æ²¡Àíרҵ£¬Ö×Áö·¢ÉúѧÑо¿ÊÒ£¬Ñо¿ÖúÀí¡£

2003Äê10ÔÂÖÁ2009Äê9ÔÂÃÀ¹ú¼ÓÖÝ´óѧ¾É½ðɽ·ÖУÌÇÄò²¡Ñо¿ÖÐÐÄ£¬ÃâÒßѧ£¬²©Ê¿ºó¡£

Éç»áÈÎÖ°£º

×ÊÁϸüÐÂÖС­¡­

¿ÆѧÑо¿£º


Ñо¿·½Ïò£º

Ö÷Òª´Óʵ÷½ÚÐÔTϸ°ûµÄÒÖÖÆ»úÀíÒÔ¼°¿ØÖƵ÷½ÚÐÔTϸ°û×ÔÉíÎȶ¨ÐԵķÖ×Ó»úÖÆÑо¿¡£

³Ðµ£¿ÆÑÐÏîÄ¿Çé¿ö£º

1¡¢microRNAÏîWnt/¦Â-cateninÐÅͨ·µÄÏî¿ØºÅ¼°ÆäÔÚÏîÏîÐÔTÏî°ûµÄ×÷Óá£

2¡¢ÖпÆÔº¡°°ÙÈ˼ƻ®¡±ÏîÄ¿¡£

¿ÆÑгɹû£º

×ÊÁϸüÐÂÖС­¡­

ÂÛÎÄרÖø£º


ÔÚNature Immunology£¬ Science£¬ The Journal of Experimental Medicine£¬Current Opinion in Immunology£¬Cancer Research£¬The Journal of ImmunologyµÈ¿¯ÎïÉÏ·¢±íÎÄÕÂ20Óàƪ¡£

³ö°æרÖø£º

×ÊÁϸüÐÂÖС­¡­

·¢±íÂÛÎÄ£º

1. Tomura M, Zhou XY, Maruo S, Ahn HJ, Hamaoka T, Okamura H, Nakanishi K, Tanimoto T, Kurimoto M, Fujiwara H. A critical role for IL-18 in the proliferation and activation of NK1.1+ CD3- cells. J Immunol. 1998;160:4738-46.

2. Tomura M, Maruo S, Mu J, Zhou XY, Ahn HJ, Hamaoka T, Okamura H, Nakanishi K, Clark S, Kurimoto M, Fujiwara H. Differential capacities of CD4+, CD8+, and CD4-CD8- T cell subsets to express IL-18 receptor and produce IFN-gamma in response to IL-18. J Immunol. 1998;160:3759-65.

3. Yashiro-Ohtani Y, Zhou XY, Toyo-Oka K, Tai XG, Park CS, Hamaoka T, Abe R, Miyake K, Fujiwara H. Non-CD28 costimulatory molecules present in T cell rafts induce T cell costimulation by enhancing the association of TCR with rafts. J Immunol. 2000;164:1251-9.

4. Zhou XY, Yashiro-Ohtani Y, Toyo-Oka K, Park CS, Tai XG, Hamaoka T, Fujiwara H. CD5 costimulation up-regulates the signaling to extracellular signal-regulated kinase activation in CD4+CD8+ thymocytes and supports their differentiation to the CD4 lineage. J Immunol. 2000;164:1260-8.

5. Park CS, Yang YF, Zhou XY, Toyooka K, Yashiro-Ohtani Y, Park WR, Tomura M, Tai XG, Hamaoka T, Fujiwara H. Reversible CD8 expression induced by common cytokine receptor gamma chain-dependent cytokines in a cloned CD4(+) T(h)1 cell line. Int Immunol. 2002;14:259-66.

6. Zhou XY, Yashiro-Ohtani Y, Nakahira M, Park WR, Abe R, Hamaoka T, Naramura M, Gu H, Fujiwara H. Molecular mechanisms underlying differential contribution of CD28 versus non-CD28 costimulatory molecules to IL-2 promoter activation. J Immunol. 2002;168:3847-54.

7. Gao P, Zhou XY, Yashiro-Ohtani Y, Yang YF, Sugimoto N, Ono S, Nakanishi T, Obika S, Imanishi T, Egawa T, Nagasawa T, Fujiwara H, Hamaoka T. The unique target specificity of a nonpeptide chemokine receptor antagonist: selective blockade of two Th1 chemokine receptors CCR5 and CXCR3. J Leukoc Biol. 2003;73:273-80.

8. Park WR, Nakahira M, Sugimoto N, Bian Y, Yashiro-Ohtani Y, Zhou XY, Yang YF, Hamaoka T, Fujiwara H. A mechanism underlying STAT4-mediated up-regulation of IFN-gamma induction inTCR-triggered T cells. Int Immunol. 2004;16:295-302.

9. Takeuchi N, Hiraoka S, Zhou XY, Nagafuku M, Ono S, Tsujimura T, Nakazawa M, Yura Y, Hamaoka T, Fujiwara H. Anti-HER-2/neu immune responses are induced before the development of clinical tumors but declined following tumorigenesis in HER-2/neu transgenic mice. Cancer Res. 2004;64:7588-95.

10. Yamaguchi N, Hiraoka S, Mukai T, Takeuchi N, Zhou XY, Ono S, Kogo M, Dunussi-Joannopoulos K, Ling V, Wolf S, Fujiwara H. Induction of tumor regression by administration of B7-Ig fusion proteins: mediation by type 2 CD8+ T cells and dependence on IL-4 production. J Immunol. 2004;172:1347-54.

11. Bian Y, Hiraoka S, Tomura M, Zhou XY, Yashiro-Ohtani Y, Mori Y, Shimizu J, Ono S, Dunussi-Joannopoulos K, Wolf S, Fujiwara H. The capacity of the natural ligands for CD28 to drive IL-4 expression in naive and antigen-primed CD4+ and CD8+ T cells. Int Immunol. 2005;17:73-83.

12. Earle KE, Tang Q, Zhou X, Liu W, Zhu S, Bonyhadi ML, Bluestone JA. In vitro expanded human CD4+CD25+ regulatory T cells suppress effector T cell proliferation. Clin Immunol. 2005;115:3-9.

13. Morimoto Y, Bian Y, Gao P, Yashiro-Ohtani Y, Zhou XY, Ono S, Nakahara H, Kogo M, Hamaoka T, Fujiwara H. Induction of surface CCR4 and its functionality in mouse Th2 cells is regulated differently during Th2 development. J Leukoc Biol. 2005;78:753-61.

14. Liu W, Putnam AL, Zhou X, Szot GL, Lee MR, Zhu S, Gottlieb PA, Kapranov P, Gingeras TR, Groth B, Clayberger C, Soper D, Ziegler S, Bluestone JA. CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ Tregs. J. Exp.Med. 2006 Jul 10;203(7):1701-11.

15.¡¡Gardner JM, Devoss JJ, Friedman RS, Wong DJ, Tan YX, Zhou X, Johannes KP, Su MA, Chang HY, Krummel MF, Anderson MS. Deletional tolerance mediated by extrathymic Aire-expressing cells.Science. 2008 Aug 8;321(5890):843-7.

16. Zhou X, Jeker LT, Fife BT, Zhu S, Anderson MS, McManus MT, Bluestone JA. Selective miRNA disruption in T reg cells leads to uncontrolled autoimmunity. J Exp Med. 2008 Sep 1;205(9):1983-91. Epub 2008 Aug 25.

17. Zhou X, Bailey-Bucktrout S, Jeker LT, Bluestone JA. Plasticity of CD4(+) FoxP3(+) T cells. Curr Opin Immunol. 2009 Jun;21(3):281-5. Epub 2009 Jun 6. Review.

18. Zhou X, Bailey-Bucktrout SL, Jeker LT, Penaranda C, Mart¨ªnez-Llordella M, Ashby M, Nakayama M, Rosenthal W, Bluestone JA. Instability of the transcription factor Foxp3 leads to the generation of pathogenic memory T cells in vivo. Nat Immunol. 2009 Sep;10(9):1000-7. Epub 2009 Jul 26.

ÈÙÓþ½±Àø£º


×ÊÁϸüÐÂÖС­¡­

ýÌ屨µÀ£º


ÈÃÃâÒßÖþÆðÉúÃüµÄÆÁÕÏ

¡ª¡ª¼ÇÖпÆԺ΢ÉúÎïËùÑо¿Ô±ÖÜÐñÓî

ÖÜÐñÓÉúÓÚ1972Ä꣬1993Äê±ÏÒµÓÚɽ¶«´óѧ£¬1996Äê»ñɽ¶«Å©Òµ´óѧ˶ʿѧ룬2001Äê»ñÈÕ±¾´óÚæ´óѧҽѧ²©Ê¿Ñ§Î»¡£2003ÄêÖÁ2009ÄêÔÚÃÀ¹ú¼ÓÀû¸£ÄáÑÇ´óѧ¾É½ðɽ·ÖУ£¨UCSF£©´Óʲ©Ê¿ºóÑо¿¹¤×÷¡£ÔÚNature Immunology£¬The Journal of Experimental Medicine£¬Current Opinion in Immunology£¬The Journal of ImmunologyµÈ¿¯ÎïÉÏ·¢±íÎÄÕÂ19ƪ¡£ÏÖΪÖпÆԺ΢ÉúÎïËùÑо¿Ô±£¬ÖпÆÔº¡°°ÙÈ˼ƻ®¡±ÈëÑ¡Õß¡£ËùÁìµ¼µÄµ÷½ÚÐÔTϸ°ûÑо¿×éÁ¥ÊôÓÚÖйú¿ÆѧԺ²¡Ô­Î¢ÉúÎïÓëÃâÒßѧÖصãʵÑéÊÒ£¬Ö÷ÒªÖÂÁ¦ÓÚµ÷½ÚÐÔTϸ°ûµÄÒÖÖÆ»úÀí¼°Æä×ÔÉíÎȶ¨ÐÔµ÷¿Ø»úÖƵÄÑо¿¡£

ÐËȤ³É¾ÍÃÎÏë

ÔøÓÐÃâÒßѧר¼Ò˵£º¡°ÊÀ½çÉÏÿһ¸öÈË×îºÃµÄÒ½Éú¾ÍÊÇËû×Ô¼ºµÄÃâÒßϵͳ¡£¡±

µÄÈ·£¬ÈËÌåµÄÃâÒßϵͳ¾ÍÏñһ֧ѵÁ·ÓÐËصľü¶Ó£¬±£»¤×ÅÈËÃǵĽ¡¿µ¡£ËüµÄÇ¿Èõ£¬¾ö¶¨×ÅÈËÃǵÖÓù¼²²¡ÈëÇÖʱµÄÄÜÁ¦¡£ÃâÒßϵͳ²»ÊÇij¸öÆ÷¹Ù¡¢Ï¸°ûµÈ£¬¶øÊÇÁÜ°ÍÆ÷¹ÙºÍ¸÷ÖÖÁÜ°Íϸ°ûµÄ¸´ÔÓ½áºÏ¡£Ò»µ©Óв¡¶¾»òÕß²¡¾úÇÖÈëÉíÌ壬ËüÃDZã»áÏñ¶à±øÖÖ½áºÏµÄ¾ü¶ÓÒ»Ñù£¬Á¢¿ÌÁªºÏÆðÀ´£¬Ê¹Óò»Í¬µÄÎäÆ÷ͶÈëÕ½¶·£¬ÏûÃðÒ»ÇÐÈëÇÖÕß¡£ÓÐÁËÕâ֧ǿ׳µÄ¾ü¶Ó£¬ÉíÌå¿ÉÒÔËæʱÏûÃðËùÓÐÈëÇÖÕߣ¬ÉõÖÁ°üÀ¨Ò»Ð©Í»±äµÄ°©Ï¸°û¡£

µ«ÊÇ£¬ÃâÒßϵͳÔõôȥʶ±ðÍâÔ´µÄ²¡Ô­Î¢ÉúÎï¸ÐȾ£¿ÃâÒßϵͳµÄÌØÒìÐÔÊÇÔõôÀ´µÄ£¬ËüΪʲô»áÌØÒìµØÖ»Çå³ý²¡Ô­¶ø²»¹¥»÷ÈË×Ô¼ºµÄ»úÌ壿

¶Ô´Ë£¬ÖпÆԺ΢ÉúÎïËù²¡Ô­Î¢ÉúÎïÓëÃâÒßѧÖصãʵÑéÊÒÑо¿Ô±ÖÜÐñÓî˵£º¡°ÕâÊÇÒ»¸öºÜÓÐÒâ˼µÄÎÊÌâ¡£¡±

ÈËÃdz£Ëµ£¬ÐËȤÊÇ×îºÃµÄÀÏʦ£¬ÖÜÐñÓîÕýÊÇÔÚÐËȤµÄÇ£ÒýϽøÈëÈËÌåÃâÒßѧÁìÓòµÄÑо¿¡£

ÖÜÐñÓî´óѧѧµÄÊÇ΢ÉúÎïѧרҵ£¬¶Ô²¡Ô­Î¢ÉúÎïÓгõ²½Á˽⡣³öÓÚ¶ÔÑо¿ÈËÌå¼²²¡µÄÐËȤ£¬Ò²±§×ÅΪÈËÌ彡¿µ×÷³ö¹±Ï×µÄÐÅÄת¶ø½øÈëҽѧÁìÓò¡£Ë¶Ê¿±ÏÒµºó£¬ÖÜÐñÓÈÕ±¾´óÚæ´óѧҽѧ²¿Toshiyuki HamaokaʵÑéÊÒ¹¥¶Á²©Ê¿Ñ§Î»£¬Ñо¿ÓÃÃâÒßϵͳÒÖÖÆÖ×ÁöµÄ»úÀí¡£Õâ¶Îʱ¼äÀÖÜÐñÓî½ÓÊÜÁ˹淶µÄ¿ÆÑÐѵÁ·£¬µ«Êǹ¥¿ËÈËÀ༲²¡µÄÇ¿ÁÒÔ¸ÍûʹËû¼ÌÐøÔ¶¸°ÃÀ¹ú¡£2003Ä꣬ÖÜÐñÓîÀ´µ½ÃÀ¹ú¼ÓÖÝ´óѧ¾É½ðɽ·ÖУÖøÃûÃâÒßѧ¼ÒJeffrey A. BluestoneʵÑéÊÒ×ö²©Ê¿ºó¡£ÕâÀïÓпª·ÅµÄѧÊõ˼Ï룬ÓÐÏȽøµÄʵÑéÉ豸£¬ÖÜÐñÓîÈçÓãµÃË®£¬ÔËÓÃÒÅ´«²Ù×÷µÄÊÖ¶Î×ö¶¯ÎïÄ£ÐÍʵÑ飬ȡµÃÀÛÀÛ˶¹û¡£2009Ä꣬ÖÜÐñÓî»Øµ½¹úÄÚ£¬ÓÉÓÚÍ»³öµÄ¿ÆÑÐÄÜÁ¦ºÍ³É¾ÍÈëÑ¡Öйú¿ÆѧԺ¡°°ÙÈ˼ƻ®¡±¡£

ÓÐÐËȤ£¬¿ÆÑоÍÊÇÒ»ÖÖÎÞÇîÏíÊÜ£¬ÕýÈç¹ÅÈËËùÔÆ£º¡°ÖªÖ®Õß²»ÈçºÃÖªÕߣ¬ºÃÖªÕß²»ÈçÀÖÖªÕß¡£¡±ÔÚҽѧÃâÒßÁìÓò£¬ÖÜÐñÓîÕýÊÇÄǸö¡°ÀÖÖªÕß¡±¡£¶ÔÓÚÄÇЩÓÃÈâÑÛ¿´²»¼ûÃþ²»×ŵÄÈËÌåϸ°ûÈçºÎÖþÆðÿ¸öÈËÉúÃüµÄÆÁÕÏ£¬Ëû³äÂúÁ˺ÃÆ棬Ëû´ø×ÅÕâÑùµÄºÃÆæÔÚ¿ÆÑеĵÀ·ÉÏÖ´×ŵØÇ°ÐУ¬ã«ÒâµØáäáà¡£

Ö´×ÅͨÍù³É¹¦

ÐËȤºÍ¼á³Ö£¬ÊÇͨÏò¿ÆÑгɹ¦µÄÁ½¿ÅÆôÃ÷ÐÇ¡£Òò´Ë£¬ÓÐÐËȤΪʼ£¬»¹ÒªÒÔÒãÁ¦Ïà°é¡£

´ÓÈÕ±¾µ½ÃÀ¹ú£¬´ÓÃÀ¹úµ½»Øµ½¹úÄÚ£¬ÖÜÐñÓî¶àÄêÀ´Ò»Ö±¼á³ÖTϸ°ûÃâÒßѧ·½ÃæµÄÑо¿¹¤×÷£¬Ê®¶àÄêÀ´³Á½þÓÚ´Ë£¬Àִ˲»Æ£¡£

»úÌåµÄÃâÒßÄÜÁ¦¿É´óÖ·ÖΪÌØÒìÐÔÃâÒßÓë·ÇÌØÒìÐÔÃâÒßÁ½ÖÖ¡£·ÇÌØÒìÐÔÃâÒßÊÇָƤ·ô¡¢Õ³Ä¤¡¢ÌåÒºÖеÄɱ¾úÎïÖʺÍÍÌÊÉϸ°ûµÈÓëÈËÌåµÄ×éÖ¯½á¹¹ºÍÉúÀí»úÄÜÃÜÇÐÏà¹ØµÄÃâÒß¹¦ÄÜ£»ÌØÒìÐÔÃâÒßÊÇ»úÌåÔÚºóÌìÊÜÄÚÍâ»·¾³ÒòËصĴ̼¤¶ø»ñµÃµÄÃâÒß¹¦ÄÜ£¬Ö÷ÒªÓɸ÷ÖÖÁÜ°Íϸ°ûµ£µ±£¬Tϸ°û´¦ÓÚÌØÒìÐÔÃâÒßÓ¦´ðµÄÖÐÐÄλÖá£ËüÄÜʶ±ðÔٴνӴ¥µÄÏàͬ¿¹Ô­£¬²¢×÷³öÏàÓ¦µÄ·´Ó¦£¬ÊÇÉíÌåÖеÖÓù¼²²¡¸ÐȾ¡¢Ö×ÁöÐγɵÄÓ¢Ó¶·Ê¿¡£

ÖÜÐñÓîÈÏΪ£¬ÎÒÃǶ¼Éú»îÔÚ³äÂúϸ¾úÓ벡¶¾µÄ»·¾³Ï£¬¿¿µÄ¾ÍÊÇÎÒÃÇÌåÄÚÓкÜÇ¿µÄÃâÒßϵͳ£¬ËüÄÜÌØÒìÐÔµØʶ±ð²¢Çå³ý¸÷ÖÖ²¡Ô­Î¢ÉúÎʹ»úÌå²úÉú±£»¤ÐÔÃâÒßÓ¦´ð¡£µ«ÊÇ£¬Õâ¸öϵͳÔÚ½¨ÔìʱÓв¿·Ö²»ÍêÉƵĵط½£¬ËüÓÐʱºò»á³ö´í£¬²¢¹¥»÷ÈË×Ô¼ºµÄÉíÌ塣ΪÁ˽â¾öÕâ¸öÎÊÌ⣬»úÌ廹¾ß±¸¶ÔÃâÒßϸ°û½øÐе÷¿ØµÄÄÜÁ¦£¬Ê¹ÃâÒßϸ°ûÖ»Õë¶Ô²»Í¬µÄ²¡Ô­Î¢ÉúÎï×÷³öÏàÓ¦µÄ·´Ó¦¡£µ÷½ÚÐÔTϸ°û£¨Treg£©ÕýÊÇÔÚÃâÒßµ÷¿ØÖÐÆð¾ö¶¨ÐÔ×÷ÓõÄÒ»ÖÖϸ°û£¬ÄÜÒÖÖƶÔ×ÔÉí¿¹Ô­ÓꦵÄÃâÒß·´Ó¦£¬Î¬³Ö»úÌåµÄÕý³£ÃâÒßƽºâ£¬Ê¹»úÌå²»ÖÁÓÚ²úÉú×ÔÉíÃâÒß¼²²¡¡£

ÔÚÕâ¸öÁìÓò£¬ÖÜÐñÓîÖ÷ÒªÖÂÁ¦ÓÚÑо¿»úÌåÃâÒßϵͳÈçºÎ¼ø¶¨ÍâÔ´ºÍÄÚÔ´£¬ÈçºÎά³Ö²»¹¥»÷×ÔÉíµÄ×éÖ¯£¨ÃâÒßÄÍÊÜ£©¡£Ò»Ð©ÑÏÖصÄÃâÒßÐÔ¼²²¡ÕýÊÇÓÉÓÚ×ÔÉíÃâÒßϵͳʧ¿ØÔì³ÉµÄ£¬ÈçÒ»ÐÍÌÇÄò²¡£¬Æä·¢²¡Ô­Òò¾ÍÊÇTϸ°ûÔÚijÖÖÒì³£µÄÌõ¼þÏ£¬·Ö²»Çå×Ô¼ºµÄ×éÖ¯ºÍÍâÔ´£¬½øÈëÒÈÔ࣬ÆÆ»µÁ˲úÉúÒȵºËصÄÒȵº£¬ÖÂʹÈËÌåÎÞ·¨²úÉúÒȵºËØ¡£ÖîÈç´ËÀàÓÉÓÚTϸ°ûʧµ÷¶øÒýÆðµÄÂýÐÔ¼²²¡»¹Óкܶ࣬ÈçϵͳÐÔºì°ßÀÇ´¯£¬Àà·çʪÐԹؽÚÑ×£¬¶à·¢ÐÔÓ²»¯(MS)µÈ£¬ÖÜÐñÓîÏ£ÍûÔÚÕâ¸öÁìÓòÄÜΪ¼²²¡ÖÎÁÆ×ö³ö¹±Ïס£

ÊÂʵÉÏ£¬ÖÜÐñÓîÔçÔÚÈÕ±¾¶Á²©ÆÚ¼ä¾Í¿ªÊ¼ÁËÕâ·½ÃæµÄÑо¿£¬ÄÇʱÖ÷Òª¾Û½¹ÓÚÐØÏÙTϸ°ûµÄ·¢Óý·Ö»¯ºÍCD4ϸ°ûµÄ»î»¯»úÖÆ£¬ÔÚרҵÆÚ¿¯ÉÏ·¢±í¶àƪÂÛÎÄ¡£´Ëºó£¬ÖÜÐñÓîÓÖÔÚµ÷½ÚÐÔTϸ°ûµÄÒÖÖÆ»úÀíÒÔ¼°¿ØÖƵ÷½ÚÐÔTϸ°û×ÔÉíÎȶ¨ÐԵķÖ×Ó»úÖÆÑо¿ÉÏÈ¡µÃÍ»ÆÆ£¬ÀûÓÃFoxP3-GFP Cre/Rosa26 loxP stop loxP YFPË«±¨¸æ»ùÒòСÊóµÄÑо¿Ê×´ÎÔÚÌåÄÚ½ÒʾÁËÐÂÐÍTϸ°ûÑÇȺµÄexFoxp3µÄ´æÔÚ¡£ÖÜÐñÓîµÄÁíÒ»¹¤×÷ÊÇ֤ʵСRNA(microRNA) ¶ÔÓÚµ÷½ÚÐÔTϸ°ûµÄÎȶ¨Î¬³Ö¼°ÆäÒÖÖƹ¦Äܵȷ½ÃæÆðµ½²»¿É·Ö¸îµÄ×÷Óá£ÕâЩÑо¿³É¹ûÔÚ¹ú¼ÊÖªÃûµÄҽѧºÍÃâÒßѧÆÚ¿¯ÉÏ·¢±íºó£¬ÒýÆð¹ú¼ÊѧÊõ½ç¼«´ó¹Ø×¢¡£ÖøÃûѧÕßRichard A Flavell½ÌÊÚºÍJohn J O¡¯Shea½ÌÊÚ¶¼ÔøÏȺó¶ÔÖÜÐñÓîµÄÑо¿³É¹û½øÐÐÁËÖصã½éÉܺÍÆÀÊö£¬²¢±»ISI¸ßƵ¶ÈÒýÓá£

Ê®¶àÄêµÄÖ´×ÅʹÖÜÐñÓîÔÚÈËÌåÃâÒßѧÑо¿ÁìÓòÈ¡µÃÁËÁîÊÀ½çÖõÄ¿µÄ³É¾Í¡£ÊµÑéÊÒÍ⺮À´ÊîÍù£¬ÊµÑéÊÒÀïÂñÍ·¿à¸ÉµÄÉíÓ°È´Ò»ÈçÍùÎô¡£Óйý´ìÕÛ£¬ÓйýÕÏ°­£¬È´´ÓûÏë¹ý·ÅÆú¡£¡°¼á³Ö£¬Ï£Íû¾ÍÔÚ²»Ô¶´¦µÄ¹Õ½Ç¡£¡±ÕâÊÇËûÓöµ½À§ÄÑʱ¶Ô×Ô¼ºËµµÄ»°¡£

´´ÐµãÁÁδÀ´

2009Ä꣬ÖÜÐñÓî×÷ΪÖйú¿ÆѧԺ¡°°ÙÈ˼ƻ®¡±Òý½øÈ˲Żعúºó£¬½øÈëÖпÆԺ΢ÉúÎïËù²¡Ô­Î¢ÉúÎïÓëÃâÒßѧÖصãʵÑéÊÒ£¬×齨Á˵÷½ÚÐÔTϸ°ûÑо¿×飬µ£ÈθºÔðÈË£¬¼ÌÐøÖÂÁ¦ÓÚµ÷½ÚÐÔTϸ°ûµÄÒÖÖÆ»úÀí¼°Æä×ÔÉíÎȶ¨ÐÔµ÷¿Ø»úÖƵÄÑо¿¡£

ÓÐÁ˶ÀÁ¢µÄÎę̀£¬ÖÜÐñÓî¾ö¶¨´óÕ¹ÉíÊÖ¡£ÔÚ´óÁ¦½¨ÉèʵÑéÊҵĻù´¡ÉÏ£¬ÖÜÐñÓîºÜ¿ì½¨³ÉÁËÒ»¸öת»ùÒòƽ̨£¬¿ªÕ¹´óƬ¶ÎDNA£¨BAC£©µÄת»ùÒòСÊóÑо¿¡£ÀûÓÃÕâ¸ö¸ßЧÂʵÄƽ̨£¬ÖÜÐñÓîÓÚ2010ÄêÉêÇëÁ˹ú¼Ò×ÔÈ»¿Æѧ»ù½ðÃæÉÏÏîÄ¿¡°microRNA¶ÔWnt/¦Â-cateninÐźÅͨ·µÄµ÷¿Ø¼°ÆäÔÚµ÷½ÚÐÔTϸ°ûµÄ×÷Óᱡ£ÖÜÐñÓî˵£º¡°µ÷½ÚÐÔTϸ°ûÃâÒßµ÷½ÚµÄ»úÀí¼°Æä¿ØÖƹý³Ì¡¢¿ØÖÆ»úÖÆ£¬ÊÇҽѧÉúÎïѧ»ù´¡Ñо¿µÄÖØÒªÎÊÌ⣬ÎÒÃÇÕâ¸öÏîÄ¿µÄÑо¿½«¼«´óµØÉ¶ÔÕâ¸öÎÊÌâµÄÁ˽⡣¡±ÔËÓÃTregÌØÒìÐÔÇóýСÊóÄ£ÐÍ£¬Ç°ÆÚ¹¤×÷ÒÑ֤ʵСRNA¶Ôµ÷½ÚÐÔTϸ°ûÓв»¿É·Ö¸îµÄ×÷Ó㬲¢·¢ÏÖÔÚСRNAȱÏݵÄTregÖÐÐí¶à°üº¬¦Â-cateninÔÚÄÚµÄWntÐźÅͨ·»ùÒò¸ßˮƽµÄ±í´ï£¬Ëæ×ÅÑо¿µÄ½øÕ¹£¬½øÒ»²½µÄ¹¤×÷±íÃ÷³ÖÐø¼¤»îWntÐźÅͨ·»áÒýÆðµ÷½ÚÐÔTϸ°ûµÄ»îÐÔɥʧ¡£ÔÚ´Ë»ù´¡ÉÏ£¬¸ÃÏîÄ¿Ö¼ÔÚÕÒµ½Ó°ÏìWnt/¦Â-cateninÐźÅͨ·µÄСRNA·Ö×Ó¼°Ñо¿ÆäÔÚµ÷½ÚÐÔTϸ°ûµÄ×÷Óá£

¿ÆѧÑо¿Ö»ÓеÚÒ»£¬Ã»Óеڶþ£¬¾ö²»¿ÉÖظ´±ðÈ˵Ť×÷¡£ÕâЩÑо¿ÄÚÈݺÍѧÊõ˼Ïë¾ùÀ´×ÔÖÜÐñÓîµÄÔ­´´¡£¼øÓÚµ÷½ÚÐÔTϸ°ûÔÚά³Ö×ÔÉíÃâÒßÄÍÊܵÄÖÐÐÄ×÷Óã¬Í¨¹ýÓÐЧ¿ØÖÆWntͨ·À´µ÷½Ú£¨ÔöÇ¿»ò¼õÈõ£©µ÷½ÚÐÔTϸ°ûµÄ»îÐÔ½«ÎªÖÎÁÆ°©Ö¢¡¢×ÔÉíÃâÒß¼²²¡¡¢ÂýÐÔ¸ÐȾ¡¢ÒÆÖ²ÈÌÄÍÐÔµÈÐí¶à·½ÃæÌṩеĻúÓö¡£

³ý´ËÖ®Í⣬ÖÜÐñÓ³Ðµ£ÁË¡°°¬×̲¡ºÍ²¡¶¾ÐÔ¸ÎÑ×µÈÖØ´ó´«È¾²¡·ÀÖΡ±¿Æ¼¼ÖØ´óרÏî¡°¿¹Ô­Tϸ°û±íλµÄ¸ßͨÁ¿É¸Ñ¡ºÍ²â¶¨¼¼Êõ¡±µÈ¿ÎÌ⣬ÆÚ´ýÔÚÖØ´ó´«È¾²¡µÄ·ÀÖÎÉÏÓÐËù½¨Ê÷¡£

ѧ¸ßΪʦ£¬ÉíÕýΪ·¶¡£Èç½ñ£¬Äê¼ÍÇáÇáµÄÖÜÐñÓîÒÑÊÇÖпÆԺ΢ÉúÎïËùµÄ²©Ê¿Éúµ¼Ê¦¡£Ãæ¶Ô³õÈë¿ÆѧµîÌõÄÄêÇáÈË£¬ÖÜÐñÓî×ÛºÏÖÐÎ÷·½½ÌѧµÄ³¤´¦£¬ÎüÊÕÁôѧÆÚ¼ä¶Ô×Ô¼ºÓ°ÏìÉîÔ¶µÄÈÕ±¾¿ÆÑеĹ淶ÐÔºÍÃÀ¹ú˼άµÄ×ÔÓɶȣ¬¼ÈÑϸñѵÁ·Ñ§ÉúµÄ¿ÆÑÐÄÜÁ¦£¬ÓÖ¹ÄÀø¶ÀÁ¢Ë¼¿¼£¬³ä·Ö·¢»Óÿ¸öÈ˵Ĵ´ÔìÁ¦£¬Îª¿ÆѧÑо¿µÄδÀ´ÅàÑø¸ü¶àµÄ´´ÐÂÐÍÈ˲š£

¶Ô¿ÆÑеÄÈȳÀÊÇÖÜÐñÓî²»¶Ï·ÜÓÂÏòÇ°µÄÔ´Ô´¶¯Á¦£¬¶ÔÐÅÄîµÄ¼á³ÖÊÇÖÜÐñÓî¼áÊØ¿ÆÑÐÕóµØµÄ¾«ÉñÖ§Öù¡£´ø×ÅÕâ·Ý¼¤ÇéÓëÖ´×Å£¬Ëû»áÔÚ¿ÆÑеÄ·ÉÏ×ߵøüºÃ¸üÔ¶ÿÿ

ÎÄÕÂÀ´Ô´£º¡¶¿ÆѧÖйúÈË¡·×÷ÕߣºÒ¶ÈðÓÅ ÁÎäìɯ 2011-11-24

ÎÄÕ¼È룺zgkjcx    ÔðÈα༭£ºzgkjcx 
  • ÉÏһƪÎÄÕ£º

  • ÏÂһƪÎÄÕ£º
  •  

    ¹ØÓÚÎÒÃÇ | ¼ÓÈëÊÕ²Ø | ÁªÏµÎÒÃÇ | ÉèΪÊ×Ò³ | ¹ã¸æ˵Ã÷ | ºÏ×÷ÏîÄ¿

    Ãû³Æ£º¿Æ¼¼´´ÐÂÍø ¹¤ÐŲ¿±¸°¸ºÅ£º¾©ICP±¸13040577ºÅ-2    ¹«°²±¸°¸ºÅ£º11010802029847
    °æȨËùÓУºÎ´¾­ÊÚȨ½ûÖ¹¸´ÖÆ»ò½¨Á¢¾µÏñ E-Mail:zgkjcx08@126.com